Omnicom Group Inc. (OCN)
Deutsche Börse Xetra · Germany · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 71.08 |
|---|---|
| 52-week range | 56.48 – 75.78 |
| Return, 1 month / 3 months | +7.5% / −1.1% |
| Return, 1 year / 3 years | +4.9% / +4.9% |
| Trend | Uptrend |
| RSI (14) | 54 |
| Volatility (1 year) | 36.0% |
| Worst drawdown (1 year) | -21.4% |
| Average daily value traded | 0.00M EUR |
| Dividend yield | 2.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Omnicom Group is a marketing and communications holding company based in the United States. Through its agencies it provides advertising, media planning and buying, public relations, branding and customer relationship management services. Its clients include large consumer brands, retailers and other businesses across many industries, served through a network of offices in markets around the world. The company also offers specialty communications services such as healthcare marketing and events.
Omnicom Group Inc. trades under the code OCN on the Deutsche Börse Xetra in Germany, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 4 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Omnicom Group Inc. (OCN) trades on the Deutsche Börse Xetra in Germany. It last closed at EUR 71.08 on 27 October 2026.
Its price-based Market X-Ray is 52 out of 100 (a fair price profile), ranking 362 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 4.9% and over the last three months it fell 1.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Deutsche Börse Xetra
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 72 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 5.9% | ||
| From 52-week high | -5.2% | ||
| Momentum | 54 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -1.1% | ||
| 6-month return | 6.0% | ||
| 12-month return, skipping the last month | -2.4% | ||
| Stability (higher is calmer) | 62 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 36.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -21.4% | ||
| Liquidity | 8 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.00M EUR | ||
| Zero-volume days | 31.7% | ||
| Income | 35 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.7% | ||
| Years with dividends | 4 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | −0.1% |
|---|---|
| 1 month | +7.5% |
| 3 months | −1.1% |
| 6 months | +6.0% |
| 1 year | +4.9% |
| 3 years | +4.9% |
| 5 years | +25.5% |
Signals
| 50-day / 200-day average | 69.99 / 67.15 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.46 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 18 Sep 2026 | USD 0.7116 |
| 11 Mar 2026 | USD 0.7116 |
| 19 Dec 2025 | USD 0.7116 |
| 20 Sep 2022 | USD 0.6227 |
| 9 Jun 2022 | USD 0.6227 |
| 9 Mar 2022 | USD 0.6227 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Deutsche Börse Xetra; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.